Noa Krawczyk
Noa Krawczyk, PhD
NYU Langone Health, Division of Epidemiology, Center for Opioid Epidemiology and Policy, Department of Population Health - Assistant Professor
PhD, Mental Health, Johns Hopkins Bloomberg School of Public Health
BA, Biology, Hunter College at the City University of New York – Macaulay Honors College
Research Interests
Substance use, Opioids, Overdose, Health services, Mental health, Criminal justice, Treatment
Noa Krawczyk is an Assistant Professor in the Department of Population Health at NYU School of Medicine and a member of the Center for Opioid Epidemiology and Policy. She completed her PhD in the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health, where she studied substance use epidemiology, and previously worked as a Fulbright research scholar to study treatment and health services among cocaine users in Brazil. Her research focuses on studying ways to address barriers to evidence-based treatment for opioid use disorders and improving quality and effectiveness of care, especially among vulnerable groups such as persons with criminal justice involvement. Her work centers on bridging research and practice by collaborating with health organizations, public health and government agencies and advancing science that can help inform evidence-based policies and practices that reduce harm and promote long term recovery.
Principal Investigator, Beyond Treatment Initiation: Enhancing Opioid Use Disorder Care Transitions Across Health System Touchpoints. Active
Principal Investigator, Trends in Psychosis Related to Hospitalizations Among Youth Following Cannabis Legalization in Colorado. Completed


Cerda M, Hamilton AD, Hyder A, Rutherford C, Bobashev G, Epstein JM, Hatna E, Krawczyk N, El-Bassel N, Feaster DJ, Keyes KM (2024).
Simulating the simultaneous impact of medication for opioid use disorder and naloxone on opioid overdose death in eight New York counties
Epidemiology, 35 (3), 418-429. doi: 10.1097/EDE.0000000000001703.

Borquez I, Cerda M, Gonzalez-Santa Cruz A, Krawczyk N, Castillo-Carniglia A (2024).
Longitudinal trajectories of substance use disorder treatment use: A latent class growth analysis using a national cohort in Chile
Addiction, 119 (4), 753-765. doi: 10.1111/add.16412.

Krawczyk N, Rivera BD, Chang JE, Lindenfeld Z, Franz B (2024).
Initiatives to support the transition of patients with substance use disorders from acute care to community-based services among a national sample of nonprofit hospitals
Journal of Addiction Medicine, 18 (2), 115-121. doi: 10.1097/ADM.0000000000001250. PMCID: PMC10939963.

Burke KN, Krawczyk N, Li Y, Byrne L, Desai IK, Bandara S, Feder KA (2024).
Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership
Journal of Substance Use and Addiction Treatment [Epub 2024 Mar 16]. doi: 10.1016/j.josat.2024.209351.

Lim S, Cherian T, Katyal M, Goldfeld KS, McDonald R, Wiewel E, Khan M, Krawczyk N, Braunstein S, Murphy SM, Jalali A, Jeng PJ, Rosner Z, MacDonald R, Lee JD (2024).
Jail-based medication for opioid use disorder and patterns of reincarceration and acute care use after release: A sequence analysis
Journal of Substance Use and Addiction Treatment, 158, 209254. doi: 10.1016/j.josat.2023.209254. PMCID: PMC10947890.


Krawczyk N, Buresh M, Gordon MS, Blue TR, Fingerhood MI, Agus D (2019).
Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap
Journal of Substance Abuse Treatment, 103, 1-8. doi: 10.1016/j.jsat.2019.05.002. PMCID: PMC6612429.

Krawczyk N, Picher CE, Feder KA, Saloner B (2017).
Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine
Health Affairs, 36 (12), 2046-2053. doi: 10.1377/hlthaff.2017.0890. PMCID: PMC6035729.

Dr. Krawczyk's MyBibliography Profile
Selected Press